Inherited genetic variant predisposes to aggressive but not indolent prostate cancer

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 5, 2010, Pages 2136-2140

  Xu, Jianfeng ^a   Zheng, Siqun Lilly ^a   Isaacs, Sarah D ^b   Wiley, Kathleen E ^b   Wiklund, Fredrik ^c   Sun, Jielin ^a   Kader, A Karim ^a   Li, Ge ^a   Purcell, Lina D ^a   Kim, Seong Tae ^a   Hsu, Fang Chi ^a   Stattin, Pär ^d   Hugosson, Jonas ^e   Adolfsson, Jan ^c   Walsh, Patrick C ^b   Trent, Jeffrey M ^f   Duggan, David ^f   Carpten, John ^f   Grönberg, Henrik ^c   Isaacs, William B ^b  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b DEPARTMENT OF PATHOLOGY   (United States)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f TRANSLATIONAL GENOMICS RESEARCH INSTITUTE   (United States)

Author keywords

Association; Genetics; Gleason grade; SNP; Stage

Indexed keywords

ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GENE FREQUENCY; GENETIC VARIABILITY; GENOME; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SWEDEN; UNITED STATES;

GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENETIC VARIATION; GENOTYPE; HUMANS; MALE; NEOPLASM INVASIVENESS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSTATIC NEOPLASMS; REGISTRIES; SWEDEN; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 76649096023     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0914061107     Document Type: Article

References (43)

1. Jemal A, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249.
2. Schröder FH, et al. ERSPC Investigators (2009) Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 360:1320-1328.
3. Andriole GL, et al. PLCO Project Team (2009) Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 360:1310-1319.
4. Schaid DJ, et al. Investigators of the International Consortium for Prostate Cancer Genetics (2006) Pooled genome linkage scan of aggressive prostate cancer: Results from the International Consortium for Prostate Cancer Genetics. Hum Genet 120: 471-485.
5. Lindström LS, et al. (2007) Familial concordance in cancer survival: A Swedish population-based study. Lancet Oncol 8:1001-1006.
6. Amundadottir LT, et al. (2006) A common variant associated with prostate cancer in European and African populations. Nat Genet 38:652-658.
7. Freedman ML, et al. (2006) Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men. Proc Natl Acad Sci USA 103:14068-14073.
8. Gudmundsson J, et al. (2007) Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat Genet 39:631-637.
9. Yeager M, et al. (2007) Genome-wide association study of prostate cancer identifies a second risk locus at 8q24. Nat Genet 39:645-649.
10. Gudmundsson J, et al. (2007) Two variants on chromosome 17 confer prostate cancer risk, and the one in TCF2 protects against type 2 diabetes. Nat Genet 39:977-983.
11. Thomas G, et al. (2008) Multiple loci identified in a genome-wide association study of prostate cancer. Nat Genet 40:310-315.
12. Gudmundsson J, et al. (2008) Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. Nat Genet 40:281-283.
13. Eeles RA, et al. UK Genetic Prostate Cancer Study Collaborators; British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators (2008) Multiple newly identified loci associated with prostate cancer susceptibility. Nat Genet 40:316-321.
14. Duggan D, et al. (2007) Two genome-wide association studies of aggressive prostate cancer implicate putative prostate tumor suppressor gene DAB2IP. J Natl Cancer Inst 99:1836-1844.
15. Haiman CA, et al. (2007) Multiple regions within 8q24 independently affect risk for prostate cancer. Nat Genet 39:638-644.
16. Zheng SL, et al. (2007) Additive effects of two unlinked loci at 8q24 are associated with a considerable fraction of prostate cancer among European Americans. J Natl Cancer Inst 99:1525-1533.
17. Sun J, et al. (2008) Evidence for two independent prostate cancer risk-associated loci in the HNF1B gene at 17q12. Nat Genet 40:1153-1155.
18. Sun J, et al. (2009) Sequence variants at 22q13 are associated with prostate cancer risk. Cancer Res 69:10-15.
19. Chang BL, et al. (2009) Fine mapping association study and functional analysis implicate a SNP in MSMB at 10q11 as a causal variant for prostate cancer risk. Hum Mol Genet 18:1368-1375.
20. Hsu FC, et al. (2009) A novel prostate cancer susceptibility locus at 19q13. Cancer Res 69:2720-2723.
21. Zheng SL, et al. (2009) Two independent prostate cancer risk-associated loci at 11q13. Cancer Epidemiol Biomarkers Prev 18:1815-1820.
22. Yeager M, et al. (2009) Identification of a new prostate cancer susceptibility locus on chromosome 8q24. Nat Genet 41:1055-1057.
23. Gudmundsson J, et al. (2009) Genome-wide association and replication studies identify four variants associated with prostate cancer susceptibility. Nat Genet 41: 1122-1126.
24. Eeles RA, et al. UK Genetic Prostate Cancer Study Collaborators/British Association of Urological Surgeons' Section of Oncology; UK ProtecT Study Collaborators; PRACTICAL Consortium (2009) Identification of seven new prostate cancer susceptibility loci through a genome-wide association study. Nat Genet 41:1116-1121.
25. Al Olama AA, et al. UK Genetic Prostate Cancer Study Collaborators/ British Association of Urological Surgeons' Section of Oncology; UK Prostate testing for cancer and Treatment study (ProtecT Study) Collaborators (2009) Multiple loci on 8q24 associated with prostate cancer susceptibility. Nat Genet 41:1058-1060.
26. Kader AK, et al. (2009) Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. Prostate 69:1195-1205.
27. Kote-Jarai Z, et al. PRACTICAL Consortium (2008) Multiple novel prostate cancer predisposition loci confirmed by an international study: The PRACTICAL Consortium. Cancer Epidemiol Biomarkers Prev 17:2052-2061.
28. Fitzgerald LM, et al. (2009) Analysis of recently identified prostate cancer susceptibility loci in a population-based study: Associations with family history and clinical features. Clin Cancer Res 15:3231-3237.
29. Wiklund FE, et al. (2009) Established prostate cancer susceptibility variants are not associated with disease outcome. Cancer Epidemiol Biomarkers Prev 18:1659-1662.
30. Gelmann EP (2008) Complexities of prostate-cancer risk. N Engl J Med 358:961-963.
31. Witte JS (2009) Prostate cancer genomics: Towards a new understanding. Nat Rev Genet 10:77-82.
32. Epstein JI, Allsbrook WC, Jr, Amin MB, Egevad LL, ISUP Grading Committee (2005) The 2005 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. Am J Surg Pathol 29:1228-1242.
33. Hoedemaeker RF, Vis AN, Van Der Kwast TH (2000) Staging prostate cancer. Microsc Res Tech 51:423-429.
34. Lotan TL, Epstein JI (2009) Gleason grading of prostatic adenocarcinoma with glomeruloid features on needle biopsy. Hum Pathol 40:471-477.
35. Cheng I, et al. (2008) 8q24 and Prostate cancer: Association with advanced disease and meta-analysis. Eur J Hum Genet 16:496-505.
36. Helfand BT, et al. (2008) Tumor characteristics of carriers and noncarriers of the deCODE 8q24 prostate cancer susceptibility alleles. J Urol, 179:2197-2201, discussion 2202.
37. Kraft P, Hunter DJ (2009) Genetic risk prediction - are we there yet? N Engl J Med 360: 1701-1703.
38. Cooperberg MR, Broering JM, Carroll PR (2009) Risk assessment for prostate cancer metastasis and mortality at the time of diagnosis. J Natl Cancer Inst 101:878-887.
39. Lin X (2004) Functions of heparan sulfate proteoglycans in cell signaling during development. Development 131:6009-6021.
40. Stephenson AJ, et al. (2009) Prostate cancer-specific mortality after radical prostatectomy for patients treated in the prostate-specific antigen era. J Clin Oncol :27.
41. Zheng SL, et al. (2008) Cumulative association of five genetic variants with prostate cancer. N Engl J Med 358:910-919.
42. Adolfsson J, et al. (2007) Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005. Scand J Urol Nephrol 41:456-477.
43. Stattin P, et al.; National Prostate Cancer Register (2008) Surveillance and deferred treatment for localized prostate cancer. Population based study in the National Prostate Cancer Register of Sweden. J Urol, 180:2423-2429, discussion 2429-2430.